BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma

Hodgkin Lymphoma (HL) accounts for approximately 10% of lymphomas and .5% of cancer cases in the United States. An estimated 8260 new cases and 1070 deaths annually occur due to HL, with most patients affected being young adults [1]. Due to advances in treatment, the prognosis for patients diagnosed with HL is excellent, and most patients are cured with first-line therapy. However, despite the relatively high long-term overall survival (OS) for HL patients, approximately 20% to 30% of patients have refractory or relapsed disease [2].

Source: Biology of Blood and Marrow Transplantation - February 1, 2019 Category: Hematology Authors: Sara Singer, Robert Dean, Qiuhong Zhao, Nidhi Sharma, Donna Abounader, Patrick Elder, Craig C. Hofmeister, Don M. Benson, Ashley Rosko, Sam Penza, Leslie Andritsos, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Brian Bolwell, Brad Pohlman, Matt Ka Source Type: research